Min Sun Jeong is a pharmacist who is specialized in Oncology in New Brunswick, New Jersey. Patients can reach her at 1 Robert Wood Johnson Pl, New Brunswick or contact her on 732-828-3000. Active license number of Min Sun Jeong is 28RI04201700 for Oncology in New Jersey. Min Sun Jeong is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Min Sun Jeong speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Min Sun Jeong
Specialization:
Oncology
Gender:
Female
Location:
1 Robert Wood Johnson Pl, New Brunswick, New Jersey, 08901-1928
Phone:
732-828-3000
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Min Sun Jeong are as mentioned below.
NPI Number:
1073343786
NPI Enumeration Date:
06 Aug, 2024
NPI Last Update On:
06 Aug, 2024
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Min Sun Jeong are as mentioned below.
Specialization
License Number
State
Status
Oncology
28RI04201700
New Jersey
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
257b Pleasantview Dr, Piscataway, New Jersey
Zip:
08854-3402
Phone Number:
201-615-4008
Fax Number:
--
Patients can reach Min Sun Jeong at 1 Robert Wood Johnson Pl, New Brunswick, New Jersey or can call on phone at 732-828-3000.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 14 October, 2024.